Member of Lyonbiopole
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions
in the field of metabolic diseases, primarily diabetes and obesity.
The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1)
The BioChaperone® technology for the development of new generation insulins and products combining
insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an
immunoprotective biomaterial for cell transplantation, with a first application in pancreatic cells
transplantation; 4) AdoGel®, a long-acting drug delivery platform.
Adocia holds more than 25 patent families. Based in Lyon, the company has more than 80 employees.
Adocia is listed on the regulated market of EuronextTM Paris (Euronext: ADOC; ISIN: FR0011184241).
Strategic application domain: Human Medicine
Application market: Metabolic Disorders - Endocrinology, Others
Type of activity: Therapeutics, Pharma or Biotech
Technologies: Others
Created on dec. 22nd, 2005 - 80 employees
Address
115 avenue Lacassagne 69003 LYON
You must be logged in and a member of Lyonbiopôle to see the contacts.
